Charles Schwab Investment Management Inc. raised its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 5.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 426,434 shares of the company's stock after purchasing an additional 23,869 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.82% of PROCEPT BioRobotics worth $34,336,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Raleigh Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $32,000. IFP Advisors Inc bought a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $58,000. Wilmington Savings Fund Society FSB bought a new position in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $64,000. Arcadia Investment Management Corp MI bought a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $64,000. Finally, Canton Hathaway LLC bought a new position in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $66,000. Institutional investors and hedge funds own 89.46% of the company's stock.
PROCEPT BioRobotics Stock Performance
Shares of NASDAQ:PRCT traded down $2.18 during mid-day trading on Tuesday, reaching $56.85. The company had a trading volume of 441,529 shares, compared to its average volume of 722,236. The company's 50-day moving average price is $70.07 and its 200-day moving average price is $79.05. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a one year low of $45.56 and a one year high of $103.81. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -29.11 and a beta of 1.05.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million. As a group, equities research analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have commented on the stock. Truist Financial reissued a "buy" rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of "Moderate Buy" and an average target price of $94.29.
View Our Latest Stock Analysis on PRCT
PROCEPT BioRobotics Company Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
